Oncolytics Biotech Inc T.ONC

JP Morgan healthcare conference

[CaseyL]

Hopefully there's more business than just showing a couple tacky posters. Hopefully this is actual business with some thing solid being but forward. Money!

[Buckhenry]

Oncy... celebrating 25 years of being hopeful... donations welcome. 

[Buckhenry]

Not interested in what we have seen in others as each one is based on their own merits.  Please quit blowing smoke unnoteable. 

[Buckhenry]

There you go again unnoteable... blowing more smoke for years. But nothing ever seems to materialize from your continued rhetoric. 

[Buckhenry]

This post has been removed in accordance with Community Policy

[Noteable]

December 27, 2024 - "  Dealmaking Dormant No More" https://www.pharmexec.com/view/dealmaking-dormant-no-more And in response to Big Pharma's pent-up demand for dealmaking and the acquisition of late stage clinical deveelopment companies   ..."Oncolytics Biotech will be presenting at the Biotech Showcase at the Hilton San Francisco Union Square on 

[Noteable]

June 20, 2024 - "“As dealmakers become more comfortable with regulatory uncertainty, we’ve seen dealmakers increasingly focused on deals in the $5 billion to $15 billion range rather than in large-scale transformative M&A,” Roel Van den Akker, PwC’s Pharma and Life Sciences Deals Lead. February 01  2024 - Merck's (MSD) CEO Robert Davis went on record by

[Noteable]

"  ... Every management team has their own style with the types of buyouts they prefer. Pfizer, AbbVie and BMS tend to take big bets, with much higher average deal sizes. In contrast, Lilly, Novo Nordisk and J&J tend to be much lower. With those larger $, Pfizer and BMS tend to acquire companies with more developed lead assets, usually Phase 3 or

[Noteable]

Clayton Dubilier & Rice completed a deal to acquire Sanofi’s consumer health unit for about €15 billion (US$16.4 billion), in what is one of the largest European transactions this year, people familiar with the matter said. That makes room for Sanofi to become an "interested party" in ONCY. We'll see in a couple of weeks.

[Noteable]

Despite the inherent specificity of an ADC, the risk of off-site toxicity exists and is an essential component while assessing the risk-benefit ratio of the treatment. Developing strategies to balance efficacy and safety is crucial, especially for newly approved therapies like T-DXd.  While the small molecule combination of the (SERD) selective estrogen receptor degrader elacestrant (Orserdu

[Noteable]

With respect to Big Pharma's M&A US$5-15 Billion valuation "sweet spot" for the acquisition of Phase 2 assets that used to treat multiple cancers with 'high value' unmet treatment needs, the valuation that Big Pharma is ready to pay is reflective of the "high value" prices that these Phase 2 assets can effectively command as treatments for those unmet medical

[Noteable]

Should read: " With respect to Big Pharma's M&A US$5-15 Billion valuation "sweet spot" for the acquisition of Phase 2 assets that can be used to treat multiple cancers with 'high value' unmet treatment needs ..."

[Noteable]

This is the first time that the ONCY Executive Team has met "en-masse" at any JP Morgan Healthcare Conference, which in most cases is when Executive teams get together to sign accretive deals and make the respective mutual M&A announcements. As previously posted, Big Pharma's M&A US$5-15 Billion valuation "sweet spot" for the acquisition of Phase 2 assets

[Noteable]

December 23, 2023 - ONCY Prepares for an 'Influential' 2025 What does ONCY mean by saying "influential"? What weight does the term "influential" hold in a M&A deal? Word games are not held in high regard for a company to employ. https://stockhouse.com/news/press-releases/2024/12/23/oncolytics-biotech-xae-highlights-2024-achievements-and-prepares-for-an

[Noteable]

"A team is defined as a group of people who perform interdependent tasks to work toward accomplishing a common mission or specific objective." https://asq.org/quality-resources/teams

[Peladawn]

Note, I get that, but that could still mean a team comprised of part of the total sum of the board of directors....somebody here talked about the entire board of directors would be required to sign any difinitive offer or agreement.....can you confirm that the entire board of directors is attending?

[Buckhenry]

I think you girls imagination has run wild here and your holding on and grasping anything you can.  Just relax and see what happens. If you don't drink maybe you should start. If you drink then maybe you should stop. All is folly.. a chasing after the wind... from the book of job 

[Noteable]

A "team" is not brought together unless each member of the team who attends a particualr meeting is asked to contribute their specialized and 'independent' knowledge in advance to specific questions or requests by an independent party.

[Noteable]

Ask ONCY what their definition of a "team' is, and why the Executive "team" is attending this specific meeting, and had attended no other in the past.

[Peladawn]

Ok...thanks Note....that certainly makes sense.

[CMHarring218431]

Don't expect you to respond to any posts of mine. Either way. So you're pretty damn sure some deal is about to be announced on the 13th just because of what the wording usually suggests or because you're just sure?

[Noteable]

ONCY is the only one who knows. And you have to ask them about their use of particular words in their press releases, which have explict definitions. For example, what does ONCY mean by "Influential" in their press release? https://stockhouse.com/news/press-releases/2024/12/23/oncolytics-biotech-xae-highlights-2024-achievements-and-prepares-for-an

[Noteable]

Synonyms of "influential" are: important, forceful and consequential. Are those positive or negative consequences? Only ONCY knows at this point in time, notwithstanding postive 3 year data from ONCY's Phase 2 breast cancer  In October 2023 ONCY reported a conservative estimate of median overall survival for the pelareorep arm as 32.1 months, demonstrating that pelareorep

[CMHarring218431]

Did they ever hire that writer person advertised on the website? Maybe, he or she could confirm what we should derive from certain expressions. I for one hope that their use of adjectives  Adheres to your chosen meaning. If so, we're in the money! 

[Noteable]

There is no doubting that postive 3 year(gold standard) mOS data from ONCY's Phase 2 Bracelet-1 breast cancer study involving the monotherapy pelareorep cohort part of intravenous pelareorep + nab-paclitaxel is 'important' and 'influential' at a time when immunochemotherapy is just coming to fruition in the views of Big Pharma companies, who are involved in seeking treatment

[Buckhenry]

Hope base on the " use of an adjective " have you folks lost your marbles or what!!!

[Buckhenry]

You folks remind me of the little red hen story. Your imagination has run away and you have become delusional  not paying attention to the fundamentals. 

[Noteable]

ONCY is showing commanding 3 year mOS primary endpoint data in the treatment of metastatic breast cancer,  which remains a cancer with an unmet treatment need. Overall Survival (OS) is the gold standard in demonstrating that a drug is effective.  Presently ONCY's Bracelet-1 Phase 2 study has demonstrated that the immunochemotherapy of pelareorep + nab-paclitaxel has 3x more

[Buckhenry]

The pumpers need to focus on convincing the would be buyers instead of worrying about who is shorting. 

[Buckhenry]

Pumpers got awfully quiet. They either cone to their senses or started their own private channel so they only hear the things that fit their emotional narrative 

[Peladawn]

Poor little Bucky.....been talking to himself for 2 days.....and still can't come up with anything intelligent to say....

[Noteable]

Repost "  ... Every management team has their own style with the types of buyouts they prefer. Pfizer, AbbVie and BMS tend to take big bets, with much higher average deal sizes. Earlier stage assets are seeing deals in the US$1-5 Billion range. Overall, the vast majority of deals had at least a Ph2 asset. For late-stage clinical development companies with I/O

[Noteable]

And in response to Big Pharma's pent-up demand for late-stage Phase 2 assets that address unmet medical treatment needs in various cancers... "Oncolytics Biotech will be presenting at the Biotech Showcase at the Hilton San Francisco Union Square on January 13, 2025, at 2:30 p.m. PST, and the Executive Team will be meeting investors in addition to current and potential partners

[spesestsemper]

You know it could just be a financing deal , I hope not at these levels .

[Noteable]

No company sends their "Executive Team" to a JP Morgan Healthcare Conference for a meeting without having negotiated a transformative "deal" in advance - unless they are absolutely "foolhardy".- which I don't think ONCY is. No company with a de-risked late-stage Phase 2 platform technology centered around a single novel biologic product that can be used to treat

[canadafan]

I agree 100% with notable, lots if activity @ the Jp Morgan investor conference. Deal or no deal on the 13th to 15th , I believe that to be the dates. There will need to be some business development, soon. and there will be. once again, I asked Bucky with his obvious abiut grade 5 education, maybe grade 6, to come up with a legitimate reply to the vast & very important clinical updates

[Noteable]

No company with a de-risked late-stage Phase 2 platform technology centered around a single novel biologic product that can be used to treat multiple cancers with unmet medical needs, and that is ready to commercialize, would be seeking to license or arranging a "financing" deal at his time in the product's life-cycle, Such development deals are conducted outside of a Business

[Buckhenry]

I wonder if the pumpers here have a backup plan after the January meeting?  Would yall be interested in buying my shares based on a 5B buyout today?  That should separate the the men from the boys  here... and might glean another dissertation from canuckcluck... that would be 3 today.. can't wait. 

[Noteable]

Rather than anyone buying your shares buckeroo, you'll be the one trying to buy back all the shares that you're currently short .. and then some.

[Buckhenry]

We all hope you girls finally got it right this time as I hate to keep imposing realism to you folks. I guess even a blind squirrel finds a nut once in a while.  

[Noteable]

I beg your pardon. You and Casey are the only ones wearing lip-stick and 9 inch stilettos buckeroo

[Noteable]

At least Casey can wear both well. She's a "girl". You on the other hand ..... I wonder ...

[Buckhenry]

Unnoteable et al reminds me of the phrase "lipstick on a pig" The phrase to put "lipstick on a pig" means making superficial or cosmetic changes to a product in a futile effort to disguise its fundamental failings.

[Noteable]

And I was thinking of you when I made that lipstick and stiletto reference of you. One of those  "girls" who you so like to dress-up and carry-on as when you try to suggest that you own this stock., and really don't. A futile effort to disguise your fundamental urge, by dressing up as the opposite and hoping that the world doesn't see your obvious angst.

[Buckhenry]

Just more lipstick on the pig this morning. We don't need the pumpers regurgitating their endless rhetoric. Let's just wait and see. Nothing they say matters anyway. 

[Noteable]

Hmmm  ... looks as though we are getting "girlish" comments from our resident "cross-dressing", "street-walker" buckeroo.

[Buckhenry]

Unnoteable please quit regurgitating the same ole stuff over and over and over. We know you need to stroke your ego constantly ... like other pumpers here but enough is enough. 

[Noteable]

And here we go again, more "girlishness" from our indispensible "cross-dresser" buckeroo  

[Buckhenry]

Sounds great unnoteable... tell folks something else earth shattering... like how wet water is...

[Noteable]

"very wet" .. so according to the biotech leaders, get ready for an increasingly active and highly anticipated M&A season in 2025 "With the cost of capital coming down and the need for pipeline replenishment remaining ever-present, the dealmaking environment is due to pick up in 2025. If this trend around reduced interest rates continues, 2025 could bring megadeals for

[Buckhenry]

Sounds awesome unnoteable... will order me a new recliner and loads of buttery popcorn to get ready for the event... should be more fun than a barrel of monkeys. 

[Noteable]

Without a doubt, his own words confirm that buckeroo is a "cross-dresser" who is not invested in ONCY 

[Buckhenry]

We are smoking today... that buyout is just around the corner... right pumpers???

[Noteable]

January 11, 2024 -  Eli Lilly and Company is in advanced talks to acquire Phase 1/2 biotechnology company Scorpion Therapeutics for $2.5 billion, the Financial Times reported on Friday, citing people briefed on the negotiations.  https://breakingthenews.net/Article/Eli-Lilly-said-to-be-in-talks-to-buy-Scorpion-Therapeutics-for-dollar2.5B/63336732 The deal is expected to be closed

[Noteable]

Blockage of PI3K/Akt activation increases reovirus synthesis and viral yield, which results in enhnaced reovirus infection and the activation of an interferon (IFN)-stimulated response (a pro-inflammatory, cytokine activated response that results in the activation of the innate immune system) - thus turning "cold' tumors (like breast and pancreatic cancer) into 'hot' tumors.

[Noteable]

January 11, 2025 - Financial Times of England - " Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5bn, according to people close to the discussions. Eli Lilly’s pursuit of privately owned Scorpion is the latest example of its strategy of redistributing the huge windfall from its

[Noteable]

I'll stop posting after this revised MOA repost  ....Inhibition of PI3K/Akt activation increases reovirus synthesis and viral yield, results in enhanced reovirus infection and the activation of an interferon (IFN)-stimulated response (a pro-inflammatory, cytokine activated response that results in the activation of the innate immune system) - thus turning "cold' tumors (like

[Noteable]

Should read: January 11, 2025 -  Eli Lilly and Company is in advanced talks to acquire Phase 1/2 biotechnology company Scorpion Therapeutics for $2.5 billion, the Financial Times reported on Friday, citing people briefed on the negotiations.  https://breakingthenews.net/Article/Eli-Lilly-said-to-be-in-talks-to-buy-Scorpion-Therapeutics-for-dollar2